Cellectar Biosciences IncCLRB
Price$1.87

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$22.3MTTM through 30 Jun 2026
Free Cash Flow -$19.5MTTM through 30 Jun 2026

Margins

Current

Returns

-187.5%ROA

Balance Sheet Health

Debt / Equity0.49x
Current Ratio1.90x
Net Debt-$6.7Mnet cash position
Cash & Equivalents$34M

Quality Metrics

Altman Z-Score-10.04
Piotroski F-Score3 / 9
Earnings-Beat Rate100.0%

Multi-Year Trend

Diluted EPS-$2.21TTM
'20'21'22'23'24'25
FY2025: $-8.35

Dividend

No dividend

Capital Allocation

R&D Spend$13.2M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.